세계의 분만 후 출혈 치료 시장(2023-2030년)

Overview

The postpartum hemorrhage treatment market trends show rising research owing to the rising technological advancements and collaborations among researchers. The biggest cause of maternal death globally is postpartum hemorrhage (PPH), which is defined as the bleeding of over 500 milliliters within 24 hours of giving delivery.

It affects approximately 14 million women annually and contributes to over 70 000 deaths, the most of which occur in low- and middle-income countries, or one every six minutes according to World Health Organization. Furthermore, rising treatments for postpartum hemorrhage due to the rising availability of approved technologies and increase in the number of deaths associated with post partum hemorrhage in the market is driving up the postpartum hemorrhage treatment market size.

The market is experiencing a growth in demand for treatment from North America as a result of the rising advancements in this field. With significant competitors like Teleflex Incorporated, Cook, Utah Medical Products, Inc., and Organon group of companies actively operating in the market, the market will grow in upcoming time.

Dynamics

Growing Research and Development by Research Organizations Drive the Growth of the Postpartum Hemorrhage Treatment Market

Postpartum hemorrhage treatment technology is currently widely applied in molecular medicine, particularly for the identification of biomarkers. According to a landmark study released by researchers from the University of Birmingham and the World Health Organization (WHO), a novel approach known as E-MOTIVE may significantly reduce mortality caused by childbirth-related bleeding.

The suggested E-MOTIVE kit comprises a blood-collection drape for the early and precise detection of PPH. An emergency treatment package that includes uterine massage, drugs to compress the womb and cease the bleeding, administering intravenous fluids, an assessment, and, if necessary, escalation to advanced care, is added to this when it is indicated.

An implementation plan that included specialized training, postpartum hemorrhage trolleys or carry cases, enlisting the help of local champions, audits, and feedback was used to support the E-MOTIVE intervention during the experiment. Midwives can complete every step of the E-MOTIVE intervention. The market is predicted to take the lead throughout the forecast period owing to high research studies.

Rising Strategic Initiatives by Government or Non-Government Organizations Creates Opportunities for the Growth of the Market

The International Federation of Gynecology and Obstetrics, or FIGO, is actively supporting efforts to lower maternal mortality and disability worldwide. Its goal statement reflects a dedication to advancing the health, human rights, and wellness of all women, particularly those who face the greatest risk of passing away or becoming disabled as a result of childbearing. When used with informed permission, FIGO's evidence-based interventions can lower the frequency of maternal illness and mortality.

In high-income countries, multimodal techniques have been used to manage diseases like PPH that have high mortality rates. The implementation of a number of interventions as well as multidisciplinary programs that establish and thoroughly address the management of a variety of pathologies make up these initiatives, which involve numerous intervention points and actors, known as "bundles" or intervention packages. Bundles provide a selection of already-existing recommendations and guidelines in a way that promotes systematized implementation and practice uniformity.

When there is high adherence to each component, FIGO believes the bundle care strategy can enhance patient outcomes. There are numerous bundles that can be used, and every health system needs to adopt one. Place the bundle in every maternity hospital and provide training for all of its components, from the time a patient arrives on the obstetrics department until the time they are transferred to higher level care.

The Side Effects Associated with Treatment will hamper the growth of the market

Convulsions (seizures), confusion, breathing issues, a fast or irregular heartbeat, dizziness, severe or persistent headaches, hives, skin rashes or itching, severe pelvic or abdominal pain, increased or persistent vaginal bleeding, rapid weight gain, and weakness are a few side effects that may or may not manifest.

Overdose symptoms include trembling, restlessness, tiredness, slurred speech, sluggish response times, and unconsciousness. There are certain potential side effects that often do not require medical treatment. As the body gets used to the medication, these side effects could go away during treatment. These elements can limit the market's expansion.

Segment Analysis

The global postpartum hemorrhage treatment market is segmented based type, treatment, sales channel and region.

Owing to High Adoption, the Oxytocin (Pitocin) from Treatment Segment Accounted for Approximately 43.2% of the Postpartum Hemorrhage Treatment Market Share

The oxytocin (Pitocin) category from treatment held the largest market share in 2022 and is expected to maintain its dominance over the forecast period due to a high demend and its high efficacy worldwide. By encouraging the generation of prostaglandins and raising the intracellular calcium ion concentrations in myometrial cells, oxytocin, which is produced by the posterior pituitary, causes an increase in uterine contractions. The upper myometrial segment undergoes regular contractions, which restrict spiral arteries and lessen uterine blood flow.

Individual differences in the amount of myometrial oxytocin receptors affect both the sensitivity and reaction of the uterus to the injection of oxytocin. Oxytocin is produced synthetically to lower the possibility of contamination from vasopressin and additional biologically active peptides. Only after the anterior shoulder delivery is oxytocin given. Oxytocin has a plasma half-life of 1 to 6 minutes. Oxytocin IV patients experience an instantaneous uterine response that lasts for about 60 minutes. In 3 to 5 minutes after administering IM oxytocin, patients experience a 2 to 3 hour long uterine response.

There is currently no dose regimen that has been demonstrated to have greater results than another. The highest oxytocin cumulative dose that is advised is 40 units. Single-dose 1-mL vials of oxytocin and multidose 10-mL vials, both containing 10 units/mL, are available. Vials must be kept at room temperature for storage.

Geographical Penetration

North America Accounted for Approximately 39.9% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment

Due to the rising need for postpartum hemorrhage medication in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for treatment for postpartum hemorrhage.

Increasing expenditure on healthcare and rising research studies, advancement of technologies for treatment purpose, and increase in pharmaceutical and women health business establishment across the region are also contributing to the growth of postpartum hemorrhage treatment market share of this region.

It is also anticipated that the main healthcare organizations' and enterprises' collaborative research projects as well as new product development, which constantly seeks to improve available alternatives, will contribute to the expanding demand. Individuals are becoming more aware of various technologies and treatment for postpartum hemorrhage that are being utilized for management purposes, leading to the expansion of the market in this region. The above-mentioned factors further proves the dominance of North America on a global scale.

Competitive Landscape

The major global players in the postpartum hemorrhage treatment market include Teleflex Incorporated, Cook, Utah Medical Products, Inc., OBSTETRX, BACTIGUARD AB, Organon group of companies, 3rd Stone Design, Pfizer Inc., American Regent, Inc. and Ferring B.V. among others.

COVID-19 Impact Analysis

Russia Ukraine Conflict Analysis

Due to the low prevalence as well as absence of major market participants in this region, it is predicted that the Russia-Ukraine conflict will not have a significant effect on the worldwide postpartum hemorrhage treatment market. The growth of the global postpartum hemorrhage treatment market, however, is anticipated to be relatively unaffected by the import and export of raw materials over the forecast period.

By Type

• Primary Postpartum Hemorrhage
• Secondary Postpartum Hemorrhage

By Treatment

• Medications
  • Oxytocin (Pitocin)
  • Carboprost Tromethamine (Hemabate)
  • Methylergonovine Maleate (Methergine)
  • Misoprostol (Cytotec)
  • Dinoprostone (Prostin E2)
  • Tranexamic Acid (Cyklokapron)

• Devices
  • Uterine Tamponade Devices
    • Foley Catheter
    • Condom Catheter
    • Bakri Temponade Balloon

• Non-Pneumatic Anti-Shock Garment
• Prefilled Injection System

By Sales Channel

• Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

• End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• On January 10, 2023, following a thorough authorization procedure, Bactiguard announces the approval of its first Medical Device Regulations (MDR) product. The latex BIP Foley Catheter, an indwelling urinary catheter featuring Bactiguard's exclusive infection prevention technology, is the subject of the MDR approval.
• On October 11, 2021, the U.S. Food and Drug Administration (FDA) has approved the Special 510(k) for technical changes to the Jada System, which is designed to control and treat abnormal Postpartum Hemorrhage Treatment or uterine bleeding when conservative management is necessary, according to Organon, a global women's health company.
• On July 26, 2021, After nearly ten years of public-private cooperation, Ferring Pharmaceuticals announced the first application of heat-stable carbetocin (Carbetocin Ferring) to stop excessive Postpartum Hemorrhage Treatment (PPH). It is now possible to employ heat-stable carbetocin in hospitals all throughout India to stop excessive bleeding after vaginal and cesarean deliveries.

DMI Opinion:

The global postpartum hemorrhage treatment market is going to see decent growth in upcoming years owing to rising usage of postpartum hemorrhage medication and novel technologies or devices that are being developed. Several researches are taking place worldwide to enhance the management of postpartum hemorrhage. Numerous advances are taking place leading to the growth of market such as uterine tempons or drapes. According to DMI the postpartum hemorrhage treatment market will see a decent growth with several novel treatments in the market.

Why Purchase the Report?

• To visualize the global postpartum hemorrhage treatment market segmentation based on type, treatment, sales channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of postpartum hemorrhage treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global postpartum hemorrhage treatment market report would provide approximately 62 tables, 54 figures and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Treatment
• 3.3. Snippet by Sales Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Growing Research and Development by Research Organizations
    • 4.1.1.2. Rising Technological Adavancements
  • 4.1.2. Restraints
    • 4.1.2.1. The Side Effects Associated with Treatment
  • 4.1.3. Opportunity
    • 4.1.3.1. Rising Strategic Initiatives by Government or Non-Government Organizations
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Primary Postpartum Hemorrhage *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Secondary Postpartum Hemorrhage

8. By Treatment

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 8.1.2. Market Attractiveness Index, By Treatment
• 8.2. Medications *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.2.3. Oxytocin (Pitocin)
  • 8.2.4. Carboprost Tromethamine (Hemabate)
  • 8.2.5. Methylergonovine Maleate (Methergine)
  • 8.2.6. Misoprostol (Cytotec)
  • 8.2.7. Dinoprostone (Prostin E2)
  • 8.2.8. Tranexamic Acid (Cyklokapron)
• 8.3. Devices
  • 8.3.1. Uterine Tamponade Devices
    • 8.3.1.1. Foley Catheter
    • 8.3.1.2. Condom Catheter
    • 8.3.1.3. Bakri Temponade Balloon
  • 8.3.2. Non-Pneumatic Anti-Shock Garment
  • 8.3.3. Prefilled Injection System

9. By Sales Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
  • 9.1.2. Market Attractiveness Index, By Sales Channel
• 9.2. Distribution Channel *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.2.3. Hospital Pharmacies
  • 9.2.4. Retail Pharmacies
  • 9.2.5. Online Pharmacies
• 9.3. End User
  • 9.3.1. Hospitals
  • 9.3.2. Ambulatory Surgical Centers
  • 9.3.3. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Spain
    • 10.3.6.5. Italy
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 12.4.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.4.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
  • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.4.4.1. Brazil
    • 12.4.4.2. Argentina
    • 12.4.4.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Teleflex Incorporated *
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Cook
• 12.3. Utah Medical Products, Inc.
• 12.4. OBSTETRX
• 12.5. BACTIGUARD AB
• 12.6. Organon group of companies
• 12.7. 3rd Stone Design
• 12.8. Pfizer Inc.
• 12.9. American Regent, Inc.
• 12.10. Ferring B.V.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us